Department of Gynecological Oncology, Oslo University Hospital (OUH), The Norwegian Radium Hospital, Postbox 4953 Nydalen 0424, Oslo, Norway.
BMC Cancer. 2014 Feb 11;14:80. doi: 10.1186/1471-2407-14-80.
Improved insight into the molecular characteristics of the different ovarian cancer subgroups is needed for developing a more individualized and optimized treatment regimen. The aim of this study was to a) identify differentially expressed miRNAs in high-grade serous ovarian carcinoma (HGSC), clear cell ovarian carcinoma (CCC) and ovarian surface epithelium (OSE), b) evaluate selected miRNAs for association with clinical parameters including survival and c) map miRNA-mRNA interactions.
Differences in miRNA expression between HGSC, CCC and OSE were analyzed by global miRNA expression profiling (Affymetrix GeneChip miRNA 2.0 Arrays, n = 12, 9 and 9, respectively), validated by RT-qPCR (n = 35, 19 and 9, respectively), and evaluated for associations with clinical parameters. For HGSC, differentially expressed miRNAs were linked to differentially expressed mRNAs identified previously.
Differentially expressed miRNAs (n = 78) between HGSC, CCC and OSE were identified (FDR < 0.01%), of which 18 were validated (p < 0.01) using RT-qPCR in an extended cohort. Compared with OSE, miR-205-5p was the most overexpressed miRNA in HGSC. miR-200 family members and miR-182-5p were the most overexpressed in HGSC and CCC compared with OSE, whereas miR-383 was the most underexpressed. miR-205-5p and miR-200 members target epithelial-mesenchymal transition (EMT) regulators, apparently being important in tumor progression. miR-509-3-5p, miR-509-5p, miR-509-3p and miR-510 were among the strongest differentiators between HGSC and CCC, all being significantly overexpressed in CCC compared with HGSC. High miR-200c-3p expression was associated with poor progression-free (p = 0.031) and overall (p = 0.026) survival in HGSC patients. Interacting miRNA and mRNA targets, including those of a TP53-related pathway presented previously, were identified in HGSC.
Several miRNAs differentially expressed between HGSC, CCC and OSE have been identified, suggesting a carcinogenetic role for these miRNAs. miR-200 family members, targeting EMT drivers, were mostly overexpressed in both subgroups, among which miR-200c-3p was associated with survival in HGSC patients. A set of miRNAs differentiates CCC from HGSC, of which miR-509-3-5p and miR-509-5p are the strongest classifiers. Several interactions between miRNAs and mRNAs in HGSC were mapped.
为了制定更个体化和优化的治疗方案,需要深入了解不同卵巢癌亚组的分子特征。本研究的目的是:a)鉴定高级别浆液性卵巢癌(HGSC)、透明细胞卵巢癌(CCC)和卵巢表面上皮(OSE)中差异表达的 miRNAs,b)评估选定的 miRNAs 与临床参数的关联,包括生存情况,c)绘制 miRNA-mRNA 相互作用图。
通过全球 miRNA 表达谱分析(Affymetrix GeneChip miRNA 2.0 Arrays,n=12、9 和 9)分析 HGSC、CCC 和 OSE 之间的 miRNA 表达差异,并用 RT-qPCR 进行验证(n=35、19 和 9),并评估与临床参数的关联。对于 HGSC,差异表达的 miRNAs 与之前鉴定的差异表达的 mRNAs 相关联。
鉴定了 HGSC、CCC 和 OSE 之间差异表达的 miRNAs(n=78)(FDR<0.01%),其中 18 个用 RT-qPCR 在扩展队列中进行了验证(p<0.01)。与 OSE 相比,miR-205-5p 在 HGSC 中表达最上调。与 OSE 相比,miR-200 家族成员和 miR-182-5p 在 HGSC 和 CCC 中表达最上调,而 miR-383 表达最低下调。miR-205-5p 和 miR-200 家族成员靶向上皮-间充质转化(EMT)调节剂,显然在肿瘤进展中起着重要作用。miR-509-3-5p、miR-509-5p、miR-509-3p 和 miR-510 是 HGSC 和 CCC 之间最强的区分物之一,在 CCC 中均显著上调。HGSC 患者中高表达 miR-200c-3p 与无进展生存期(p=0.031)和总生存期(p=0.026)不良相关。在 HGSC 中鉴定到了 miRNA 和 mRNA 靶标之间的相互作用,包括之前提出的 TP53 相关途径的靶标。
鉴定了 HGSC、CCC 和 OSE 之间差异表达的多个 miRNAs,提示这些 miRNAs 在致癌作用中起作用。HGSC 中大多数上调的 EMT 驱动子的 miR-200 家族成员,其中 miR-200c-3p 与 HGSC 患者的生存相关。一组 miRNAs 将 CCC 与 HGSC 区分开来,其中 miR-509-3-5p 和 miR-509-5p 是最强的分类器。在 HGSC 中绘制了 miRNA 和 mRNA 之间的多个相互作用。